Alkem Labs Q2 FY27 profit drops 12% to ₹675 crore despite revenue surge
Synopsis
Alkem Laboratories posted a 12% profit drop in Q2 FY27 even as revenues surged 13.8% — a classic margin squeeze. With the chronic segment outpacing the market and non-US international sales up 58%, the fundamentals look intact, but rising costs are eating into gains faster than the topline can compensate.
Key Takeaways
Alkem Laboratories reported Q2 FY27 net profit of ₹675 crore , down 11.8% from ₹765 crore in Q2 FY26.
Revenue from operations rose 13.8% to ₹4,552 crore , driven by growth in domestic and international markets.
EBITDA grew 11.3% to ₹1,025 crore , but EBITDA margin narrowed to 22.5% from 23% .
Domestic sales rose 9.5% to ₹3,027.5 crore , accounting for 68% of total sales; chronic segment grew 22.4% , outpacing the market.
International sales surged 22.3% to ₹1,454 crore ; US sales grew just 2.4% amid pricing pressure while non-US sales jumped 58% .
A one-time gain of ₹35 crore was recorded during the quarter.
Alkem Laboratories on Thursday, 12 November 2026 reported an 11.8% year-on-year decline in consolidated net profit to ₹675 crore for the second quarter of FY27 (July–September 2026), even as double-digit revenue growth in both domestic and international markets pointed to underlying business momentum. The pharmaceutical major's earnings came despite a one-time gain of ₹35 crore recorded during the quarter.
Profit and Revenue at a Glance
Consolidated net profit fell from ₹765 crore in Q2 FY26 to ₹675 crore in Q2 FY27, according to the company's stock exchange filing. Revenue from operations, however, rose a strong 13.8% year-on-year to ₹4,552 crore, up from ₹4,001 crore in the year-ago period.
At the operating level, earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 11.3% to ₹1,025 crore from ₹921 crore a year earlier. However, EBITDA margin narrowed slightly to 22.5% from 23%, signalling cost pressures even as topline momentum held up.
Domestic Business Remains the Backbone
India continued to be Alkem's largest revenue driver, with domestic sales rising 9.5% year-on-year to ₹3,027.5 crore. The domestic segment accounted for 68% of total quarterly sales, down from 70% in the corresponding period last year — reflecting the faster growth pace of international operations.
According to IQVIA data, Alkem's domestic business grew 13.8% during the quarter, broadly in line with the Indian Pharmaceutical Market. The company's chronic segment outperformed notably, expanding 22.4% against market growth of 16%, while the acute portfolio grew 12.1%. Alkem also outpaced the broader market across therapies including vitamins, minerals and nutrition, pain management, anti-diabetic, cardiac, urology, respiratory, neuro/CNS, and dermatology.
International Sales Surge, US Faces Pricing Pressure
Alkem's international business delivered robust growth, with total international sales climbing 22.3% year-on-year to ₹1,454 crore. US sales grew a modest 2.4% to ₹783 crore amid continued pricing pressure in the American generics market — a challenge that has weighed on several Indian pharma exporters. Non-US international sales surged 58% to ₹671 crore; excluding the impact of Occlutech, non-US growth stood at a still-healthy 28.6%.
What the Numbers Reveal
The divergence between strong revenue growth and declining profit points to margin compression — a pattern seen across the Indian pharmaceutical sector this earnings cycle. The slight contraction in EBITDA margin from 23% to 22.5% suggests higher operating costs are absorbing topline gains. The one-time ₹35 crore gain also cushioned what could have been a steeper profit fall.
As Alkem's chronic portfolio gains share and non-US international markets accelerate, investors will be watching whether the company can translate revenue momentum into margin recovery in the quarters ahead.
Point of View
But margins under siege. The 22.4% growth in the chronic segment is a genuine positive — chronic therapies carry better stickiness and margin potential than acute. But the US generics business, growing at just 2.4%, remains a drag, and pricing pressure in that market shows no sign of abating. The real question is whether the non-US international surge — up 58%, partly Occlutech-assisted — is structural or one-off. If Alkem can sustain 25-plus percent non-US growth independently of acquisitions, the mix shift away from a pressured US market could gradually re-rate the stock. Without that, margin recovery will remain elusive even as the topline impresses.
NationPress
12 Nov 2026
Frequently Asked Questions
What was Alkem Laboratories' net profit in Q2 FY27?
Alkem Laboratories reported a consolidated net profit of ₹675 crore in Q2 FY27 (quarter ended September 2026), an 11.8% decline from ₹765 crore in Q2 FY26. The company also recorded a one-time gain of ₹35 crore during the quarter.
Why did Alkem's profit fall despite strong revenue growth?
While revenue grew 13.8% to ₹4,552 crore, rising operating costs compressed the EBITDA margin from 23% to 22.5%, leading to a lower net profit. The profit decline reflects margin pressure absorbing topline gains, a trend seen across the pharma sector this earnings cycle.
How did Alkem's domestic business perform in Q2 FY27?
Alkem's domestic sales rose 9.5% year-on-year to ₹3,027.5 crore, accounting for 68% of total quarterly revenue. The chronic segment grew 22.4%, significantly outpacing market growth of 16%, according to IQVIA data.
How did Alkem's international business perform?
International sales grew 22.3% to ₹1,454 crore. US sales rose a modest 2.4% to ₹783 crore amid ongoing pricing pressure, while non-US international sales surged 58% to ₹671 crore, or 28.6% excluding the contribution from Occlutech.
What is Alkem Laboratories' EBITDA for Q2 FY27?
Alkem's EBITDA for Q2 FY27 stood at ₹1,025 crore, up 11.3% from ₹921 crore a year earlier. However, the EBITDA margin narrowed to 22.5% from 23% in the same period last year, indicating cost headwinds despite operational growth.
